-
公开(公告)号:EP1405852A4
公开(公告)日:2006-07-26
申请号:EP02743653
申请日:2002-06-20
申请人: DAIICHI SEIYAKU CO
发明人: OHTA TOSHIHARU , KOMORIYA SATOSHI , YOSHINO TOSHIHARU , UOTO KOUICHI , NAKAMOTO YUMI , NAITO HIROYUKI , MOCHIZUKI AKIYOSHI , NAGATA TSUTOMU , KANNO HIDEYUKI , HAGINOYA NORIYASU , YOSHIKAWA KENJI , NAGAMOCHI MASATOSHI , KOBAYASHI SYOZO , ONO MAKOTO
IPC分类号: C07D401/12 , A61K20060101 , A61K31/428 , A61K31/429 , A61K31/4365 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/454 , A61K31/4545 , A61P20060101 , A61P7/02 , A61P9/00 , A61P9/10 , A61P29/00 , C07D20060101 , C07D209/42 , C07D401/14 , C07D417/12 , C07D417/14 , C07D487/04 , C07D495/04 , C07D498/04 , C07D513/04 , C07D513/14 , C07D519/00 , C07K5/06 , C07K5/08
CPC分类号: C07D401/12 , C07D209/42 , C07D401/14 , C07D417/12 , C07D417/14 , C07D487/04 , C07D495/04 , C07D513/04 , C07D513/14 , C07K5/06191 , C07K5/0827
摘要: Compounds represented by the following general formula (1), salts thereof, solvates of the same or N-oxides of the same: Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4 (1) wherein R1 and R2 represent each hydrogen, etc.; Q1 represents optionally substituted, saturated or unsaturated 5- or 6-membered hydrocarbyl, etc.; Q2 represents a single bond, etc.; Q3 represents the following group; (wherein Q5 represents C1-8 alkylene, etc.); and T0 and T1 represent each carbonyl, etc. These compounds are useful as preventives and/or remedies for brain infarction, cerebral embolism, myocardial infarction, angina, pulmonary infarction, pulmonary embolism, Buerger’s disease, bottom venous thrombosis, disseminated intravascular coagulation, thrombosis following artificial valve/joint replacement, thrombosis and reocclusion following circulation reconstruction, systemic inflammatory responsive syndrome (SIRS), multiple organ dysfunction (MODS), thrombosis in extracorporeal circulation or blood coagulation in collecting blood.
-
公开(公告)号:EP1650205A4
公开(公告)日:2010-04-28
申请号:EP04747846
申请日:2004-07-23
申请人: DAIICHI SEIYAKU CO
发明人: ONO MAKOTO , NOGUCHI SHIGERU
IPC分类号: C07D403/12 , A61K31/404 , A61P1/00 , A61P3/10 , A61P11/06 , A61P17/06 , A61P19/02 , A61P25/00 , A61P27/16 , A61P29/00 , A61P35/04 , A61P37/02
CPC分类号: C07D403/12
-
公开(公告)号:EP1415992A4
公开(公告)日:2006-07-26
申请号:EP02762760
申请日:2002-08-08
申请人: DAIICHI SEIYAKU CO
发明人: OHTA TOSHIHARU , KOMORIYA SATOSHI , YOSHINO TOSHIHARU , UOTO KOUICHI , NAKAMOTO YUMI , NAITO HIROYUKI , MOCHIZUKI AKIYOSHI , NAGATA TSUTOMU , KANNO HIDEYUKI , HAGINOYA NORIYASU , YOSHIKAWA KENJI , NAGAMOCHI MASATOSHI , KOBAYASHI SYOZO , ONO MAKOTO
IPC分类号: C07D401/12 , A61K20060101 , A61K31/428 , A61K31/429 , A61K31/4365 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/454 , A61K31/4545 , A61K31/4709 , A61K31/4725 , A61K31/50 , A61K31/501 , A61K31/502 , A61K31/5025 , A61K31/506 , A61K31/517 , A61K31/519 , A61P20060101 , A61P7/02 , A61P9/00 , C07D20060101 , C07D209/42 , C07D401/14 , C07D417/12 , C07D417/14 , C07D487/04 , C07D495/04 , C07D498/04 , C07D513/04 , C07D513/14 , C07D519/00 , C07K5/06 , C07K5/08
CPC分类号: C07D209/42 , C07D401/12 , C07D401/14 , C07D417/12 , C07D417/14 , C07D487/04 , C07D513/04 , C07K5/06191 , C07K5/0827
摘要: Compounds represented by the following general formula (1), salts thereof, solvates of the same or N-oxides of the same: Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4 (1) wherein R1 and R2 represent each hydrogen, etc.; Q1 represents optionally substituted, saturated or unsaturated 5- or 6-membered hydrocarbyl, etc.; Q2 represents a single bond, etc.; Q3 represents the following group; (wherein Q5 represents C1-8 alkylene, etc.); and T0 and T1 represent each carbonyl, etc. These compounds are useful as preventives and/or remedies for brain infarction, cerebral embolism, myocardial infarction, angina, pulmonary infarction, pulmonary embolism, Buerger’s disease, bottom venous thrombosis, disseminated intravascular coagulation, thrombosis following artificial valve/joint replacement, thrombosis and reocclusion following circulation reconstruction, systemic inflammatory responsive syndrome (SIRS), multiple organ dysfunction (MODS), thrombosis in extracorporeal circulation or blood coagulation in collecting blood.
摘要翻译: (1)表示的化合物,其盐,相同的溶剂化物或相同的N-氧化物:Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4(1) 其中R1和R2代表每个氢等; Q1表示任选取代的饱和或不饱和的5或6元烃基等; Q2代表单键等; Q3代表以下组别; (其中Q5表示C1-8亚烷基等); 这些化合物可用作脑梗塞,脑栓塞,心肌梗塞,心绞痛,肺梗塞,肺栓塞,伯格氏病,下肢静脉血栓形成,弥散性血管内凝血,血栓形成等的预防剂和/或治疗剂 继循环重建,全身炎症反应综合征(SIRS),多器官功能障碍(MODS),体外循环中的血栓形成或血液凝固后的人工瓣膜/关节置换,血栓形成和再闭塞。
-
公开(公告)号:EP1577301A4
公开(公告)日:2009-11-11
申请号:EP03768266
申请日:2003-12-25
申请人: DAIICHI SEIYAKU CO
发明人: OHTA TOSHIHARU , KOMORIYA SATOSHI , YOSHINO TOSHIHARU , UOTO KOUICHI , NAKAMOTO YUMI , NAITO HIROYUKI , MOCHIZUKI A , NAGATA TSUTOMU , KANNO HIDEYUKI , HAGINOYA NORIYASU , YOSHIKAWA KENJI , NAGAMOCHI M , KOBAYASHI SYOZO , ONO MAKOTO
IPC分类号: C07D513/04 , C07D213/75
CPC分类号: C07D498/04 , C07D213/75 , C07D401/12 , C07D401/14 , C07D409/04 , C07D409/12 , C07D413/12 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D513/14 , C07D519/00
-
公开(公告)号:EP1457492A4
公开(公告)日:2005-03-23
申请号:EP02785977
申请日:2002-11-29
申请人: DAIICHI SEIYAKU CO
发明人: UCHIDA S , TAKAYANAGI Y , ONO MAKOTO
IPC分类号: A61K31/443 , A61P35/00 , C07D493/04 , C07D493/08
CPC分类号: A61K31/443 , C07D493/04
摘要: Crystals of (1S,2S,3R,4S,5R,8R,9S,10R,13S)-4-acetoxy-2 -benzoyloxy-9,10-[(1S)-2-(dimethylamino)ethylidenedioxy]-5,20-epoxy-1-hydroxytax-11-en-13-yl (2R,3S)-3-(tert-butoxy- carbonylamino)-3-(3-fluoro-2-pyridyl)-2-hydroxypropionate, which exhibit in the powder X-ray diffraction pattern characteristic peaks at diffraction angles (2θ) of 6.2°, 10.3°, 10.7°, 11.4°, and 12.0°; and a process for production of the crystals which comprises the step of conducting crystallization by the use of an organic solvent selected from among ketones, nitriles and mixtures of both or a mixture of the organic solvent with water.
-
公开(公告)号:EP0819676A4
公开(公告)日:1998-07-08
申请号:EP96904290
申请日:1996-03-01
申请人: DAIICHI SEIYAKU CO
发明人: SATO YUKIO , KITAOKA HIROAKI , TERADA TATSUYA , ONO MAKOTO
IPC分类号: C07D207/26 , C07D207/27 , A61K31/40 , A61K31/44 , C07D401/12
CPC分类号: C07D207/27
摘要: Substantially nonhygroscopic anhydrous crystals of compounds represented by the general formula: R2-CH2CONH-R1 (wherein R1 represents (un)substituted pyridyl or (un)substituted phenyl; and R2 represents (un)substituted 2-oxo-1-pyrrolidinyl). Drying the hydrous crystals of the above compounds at a temperature of 80 °C or above under reduced pressure yields the corresponding anhydrous crystals with a weight gain of at most 1 % caused by moisture absorption after storage at a relative humidity of 83 % and a temperature of 25 °C for 30 days. Medicines containing the above compounds in the form of anhydrous crystals are uniform in the active ingredient content.
摘要翻译: 由通式R 2 -CH 2 CONH-R 1(其中R 1代表(未)取代的吡啶基或(未)取代的苯基;和R 2代表(未)取代的2-氧代-1-吡咯烷基)代表的化合物的基本上无吸湿性的无水晶体。 上述化合物的含水结晶在80℃以上的减压下干燥,得到相对湿度83%,温度保存后的吸湿引起的重量增加为1%以下的无水结晶 25℃30天。 含有无水晶体形式的上述化合物的药物在活性成分含量上是均匀的。
-
-
-
-
-